Effects of the Japanese herbal medicine 'Inchinko-to' (TJ-135) on concanavalin A-induced hepatitis in mice

Citation
M. Yamashiki et al., Effects of the Japanese herbal medicine 'Inchinko-to' (TJ-135) on concanavalin A-induced hepatitis in mice, CLIN SCI, 99(5), 2000, pp. 421-431
Citations number
73
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Medical Research General Topics
Journal title
CLINICAL SCIENCE
ISSN journal
0143-5221 → ACNP
Volume
99
Issue
5
Year of publication
2000
Pages
421 - 431
Database
ISI
SICI code
0143-5221(200011)99:5<421:EOTJHM>2.0.ZU;2-8
Abstract
Inchinko-to (TJ-135) is a herbal medicine consisting of three kinds of crud e drugs, and in Japan it is administered mainly to patients with cholestasi s. The present study evaluated the effects of TJ-135 on concanavalin A (con A)-induced hepatitis in mice in vivo and con A-induced cytokine production in vitro. When mice were pretreated with oral TJ-135 for 1 week before int ravenous con A injection, the activities of serum aspartate aminotransferas e (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) wer e significantly decreased 8 h after con A administration (-82%, -96% and -6 6% respectively). in histological investigations, submassive hepatic necros is accompanying inflammatory cell infiltration was not observed in mice pre treated with TJ-135. Serum levels of interleukin-12 (IL-12), interferon-gam ma (IFN-gamma) and IL-2 were significantly lower in mice pretreated with TJ -135 compared with controls, while IL-IO levels were higher in these mice. Intrasplenic IL-12 levels were significantly lower in mice pretreated with TJ-135, while intrasplenic IL-10 levels were higher in these mice. In vitro , IL-10 production by splenocytes was increased by the addition of TJ-135 t o the culture medium. whereas the production of IL-12 and IFN-gamma was inh ibited. These results suggest that con A-induced hepatitis was ameliorated by pretreatment with TJ-135. With regard to the mechanism of these effects of TJ-135, we speculate that TJ-135 inhibits the production of inflammatory cytokine and enhances the production of anti-inflammatory cytokines. There fore administration of TJ-135 may be useful in patients with severe acute h epatitis accompanying cholestasis or in those with autoimmune hepatitis.